• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER

PERCHERON THERAPEUTICS LIMITED - Corporate Spotlight

0.00% ! 1.0¢
Market Cap $10.87M  !

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $10.87M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $71.80K 7.180M

Buyers (Bids)

No. Vol. Price($)
1 4649246 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 2600000 2
View Market Depth
Last trade - 15.21pm 13/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.